These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 11391126

  • 1. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.
    Heikkinen H, Nutt JG, LeWitt PA, Koller WC, Gordin A.
    Clin Neuropharmacol; 2001; 24(3):150-7. PubMed ID: 11391126
    [Abstract] [Full Text] [Related]

  • 2. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J, Kaakkola S, Ahtila S, Tuomainen P, Teräväinen H.
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [Abstract] [Full Text] [Related]

  • 3. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
    Najib J.
    Clin Ther; 2001 Jun; 23(6):802-32; discussion 771. PubMed ID: 11440283
    [Abstract] [Full Text] [Related]

  • 4. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
    Ferreira JJ, Almeida L, Cunha L, Ticmeanu M, Rosa MM, Januário C, Mitu CE, Coelho M, Correia-Guedes L, Morgadinho A, Nunes T, Wright LC, Falcão A, Sampaio C, Soares-da-Silva P.
    Clin Neuropharmacol; 2008 Jun; 31(1):2-18. PubMed ID: 18303486
    [Abstract] [Full Text] [Related]

  • 5. Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.
    Heikkinen H, Varhe A, Laine T, Puttonen J, Kela M, Kaakkola S, Reinikainen K.
    Br J Clin Pharmacol; 2002 Oct; 54(4):363-71. PubMed ID: 12392583
    [Abstract] [Full Text] [Related]

  • 6. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.
    Paija O, Laine K, Kultalahti ER, Leinonen M, Huupponen R, Gordin A, Reinikainen K.
    Clin Neuropharmacol; 2005 Oct; 28(3):115-9. PubMed ID: 15965309
    [Abstract] [Full Text] [Related]

  • 7. The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J, Sovijärvi A, Kaakkola S, Gordin A, Teräväinen H.
    Clin Neuropharmacol; 2001 Oct; 24(1):50-7. PubMed ID: 11290882
    [Abstract] [Full Text] [Related]

  • 8. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
    Rocha JF, Falcão A, Santos A, Pinto R, Lopes N, Nunes T, Wright LC, Vaz-da-Silva M, Soares-da-Silva P.
    Eur J Clin Pharmacol; 2014 Sep; 70(9):1059-71. PubMed ID: 24925090
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
    Nunes T, Machado R, Rocha JF, Fernandes-Lopes C, Costa R, Torrão L, Loureiro AI, Falcão A, Vaz-da-Silva M, Wright L, Almeida L, Soares-da-Silva P.
    Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition.
    Rouru J, Gordin A, Huupponen R, Huhtala S, Savontaus E, Korpela K, Reinikainen K, Scheinin M.
    Eur J Clin Pharmacol; 1999 Aug; 55(6):461-7. PubMed ID: 10492060
    [Abstract] [Full Text] [Related]

  • 11. Clinical advantages of COMT inhibition with entacapone - a review.
    Gordin A, Kaakkola S, Teräväinen H.
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1343-63. PubMed ID: 15340869
    [Abstract] [Full Text] [Related]

  • 12. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group.
    Rinne UK, Larsen JP, Siden A, Worm-Petersen J.
    Neurology; 1998 Nov; 51(5):1309-14. PubMed ID: 9818851
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).
    Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M, Celomen Study Group.
    Acta Neurol Scand; 2002 Apr; 105(4):245-55. PubMed ID: 11939936
    [Abstract] [Full Text] [Related]

  • 14. Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients.
    Ruottinen HM, Rinne UK.
    Clin Neuropharmacol; 1996 Jun; 19(3):222-33. PubMed ID: 8726541
    [Abstract] [Full Text] [Related]

  • 15. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease.
    Ruottinen HM, Rinne UK.
    Clin Neuropharmacol; 1996 Aug; 19(4):283-96. PubMed ID: 8828991
    [Abstract] [Full Text] [Related]

  • 16. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.
    Corvol JC, Bonnet C, Charbonnier-Beaupel F, Bonnet AM, Fiévet MH, Bellanger A, Roze E, Meliksetyan G, Ben Djebara M, Hartmann A, Lacomblez L, Vrignaud C, Zahr N, Agid Y, Costentin J, Hulot JS, Vidailhet M.
    Ann Neurol; 2011 Jan; 69(1):111-8. PubMed ID: 21280081
    [Abstract] [Full Text] [Related]

  • 17. Impact of the catechol-O-methyltransferase Val158Met polymorphism on the pharmacokinetics of L-dopa and its metabolite 3-O-methyldopa in combination with entacapone.
    Yamamoto J, Omura T, Kasamo S, Yamamoto S, Kawata M, Yonezawa A, Taruno Y, Endo H, Aizawa H, Sawamoto N, Matsubara K, Takahashi R, Tasaki Y.
    J Neural Transm (Vienna); 2021 Jan; 128(1):27-36. PubMed ID: 33136226
    [Abstract] [Full Text] [Related]

  • 18. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
    Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P, Bi-Park 1 investigators.
    Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
    [Abstract] [Full Text] [Related]

  • 19. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study.
    Brooks DJ, Sagar H, UK-Irish Entacapone Study Group.
    J Neurol Neurosurg Psychiatry; 2003 Aug; 74(8):1071-9. PubMed ID: 12876237
    [Abstract] [Full Text] [Related]

  • 20. Entacapone in the management of Parkinson's disease.
    Henchcliffe C, Waters C.
    Expert Opin Pharmacother; 2002 Jul; 3(7):957-63. PubMed ID: 12083995
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.